Article Correctness Is Author's Responsibility: Radavirsen performs well in early influenza trial

(Wiley) A phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen--an antisense oligomer that inhibits the production of certain influenza proteins -- is safe and well-tolerated in healthy individuals. Additional studies on radavirsen's potential as a treatment for influenza are warranted.
Posted in Uncategorized